What's Happening?
A recent report by BioSpace reveals that biopharma professionals in the U.S. are more likely to receive significant salary increases by changing employers rather than staying with their current companies. The 2026 U.S. Life Sciences Salary Report indicates
that while only 9% of full-time employees reported salary increases from changing jobs, those who did often saw a 10% increase. In contrast, merit-based raises typically resulted in a 3% increase. The report highlights that 75.1% of those who switched employers received at least a 6% raise, compared to only 22.6% of those who stayed. Additionally, 5% of job switchers experienced salary surges of 25% or more. The report suggests that moving from smaller to larger companies could be a factor in these substantial increases.
Why It's Important?
This trend underscores a significant shift in the biopharma job market, where professionals are increasingly motivated to change employers for better compensation. The report suggests that the current job market offers employers a wide choice of talent, reducing the need to offer substantial raises to retain employees. This dynamic could lead to increased turnover as employees seek better financial opportunities elsewhere. The findings also highlight a broader issue of salary disparities and the challenges employees face in securing raises, which could impact employee satisfaction and retention in the industry.
What's Next?
As companies continue to exercise caution in their spending, including on salaries, biopharma professionals may need to adjust their expectations for salary increases in 2026. According to Chantal Dresner, BioSpace's Vice President of Marketing, the job market's current state allows employers to be selective, potentially limiting significant salary offers. This environment may prompt more professionals to consider changing jobs to achieve their desired compensation, potentially leading to higher turnover rates in the industry.
